These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 26951309)

  • 1. Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.
    Powles T; Lackner MR; Oudard S; Escudier B; Ralph C; Brown JE; Hawkins RE; Castellano D; Rini BI; Staehler MD; Ravaud A; Lin W; O'Keeffe B; Wang Y; Lu S; Spoerke JM; Huw LY; Byrtek M; Zhu R; Ware JA; Motzer RJ
    J Clin Oncol; 2016 May; 34(14):1660-8. PubMed ID: 26951309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative Assessment of Drug Efficacy and Emergence of Resistance in Patients with Metastatic Renal Cell Carcinoma Using a Longitudinal Exposure-Tumor Growth Inhibition Model: Apitolisib (Dual PI3K/mTORC1/2 Inhibitor) Versus Everolimus (mTORC1 Inhibitor).
    Moein A; Jin JY; Wright MR; Wong H
    J Clin Pharmacol; 2024 Sep; 64(9):1101-1111. PubMed ID: 38639108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus.
    Werter IM; Huijts CM; Lougheed SM; Hamberg P; Polee MB; Tascilar M; Los M; Haanen JBAG; Helgason HH; Verheul HM; de Gruijl TD; van der Vliet HJ;
    Cancer Immunol Immunother; 2019 May; 68(5):787-798. PubMed ID: 30756132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes.
    Atkinson BJ; Cauley DH; Ng C; Millikan RE; Xiao L; Corn P; Jonasch E; Tannir NM
    BJU Int; 2014 Mar; 113(3):376-82. PubMed ID: 24053120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer.
    Treilleux I; Arnedos M; Cropet C; Wang Q; Ferrero JM; Abadie-Lacourtoisie S; Levy C; Legouffe E; Lortholary A; Pujade-Lauraine E; Bourcier AV; Eymard JC; Spaeth D; Bachelot T
    Ann Oncol; 2015 Jan; 26(1):120-125. PubMed ID: 25361980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiating mTOR inhibitors in renal cell carcinoma.
    Pal SK; Quinn DI
    Cancer Treat Rev; 2013 Nov; 39(7):709-19. PubMed ID: 23433636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma.
    McGregor BA; Xie W; Adib E; Stadler WM; Zakharia Y; Alva A; Michaelson MD; Gupta S; Lam ET; Farah S; Nassar AH; Wei XX; Kilbridge KL; Harshman L; Signoretti S; Sholl L; Kwiatkowski DJ; McKay RR; Choueiri TK
    JCO Precis Oncol; 2022 Feb; 6():e2100448. PubMed ID: 35171658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective Assessment of Translational Pharmacokinetic-Pharmacodynamic Modeling Performance: A Case Study with Apitolisib, a Dual PI3K/mTOR Inhibitor.
    Moein A; Jin JY; Wright MR; Alicke B; Wong H
    Drugs R D; 2024 Jun; 24(2):155-167. PubMed ID: 38700808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study.
    Jones VE; McIntyre KJ; Paul D; Wilks ST; Ondreyco SM; Sedlacek S; Melnyk A; Oommen SP; Wang Y; Peck SR; O'Shaughnessy JA
    Oncologist; 2019 Sep; 24(9):1153-1158. PubMed ID: 30833486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial.
    Ryan CW; Tangen CM; Heath EI; Stein MN; Meng MV; Alva AS; Pal SK; Puzanov I; Clark JI; Choueiri TK; Agarwal N; Uzzo RG; Haas NB; Synold TW; Plets M; Vaishampayan UN; Shuch BM; Thompson IM; Lara PN
    Lancet; 2023 Sep; 402(10407):1043-1051. PubMed ID: 37524096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO.
    Ray-Coquard I; Favier L; Weber B; Roemer-Becuwe C; Bougnoux P; Fabbro M; Floquet A; Joly F; Plantade A; Paraiso D; Pujade-Lauraine E
    Br J Cancer; 2013 May; 108(9):1771-7. PubMed ID: 23612453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer.
    Fukudo M; Ishibashi K; Kitada M
    Invest New Drugs; 2021 Dec; 39(6):1707-1715. PubMed ID: 34041638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemodialysis does not affect everolimus pharmacokinetics: two cases of patients with metastatic renal cell cancer.
    Thiery-Vuillemin A; Curtit E; Maurina T; Montange D; Succi C; NGuyen T; Kim S; Montcuquet P; Pivot X; Royer B
    Ann Oncol; 2012 Nov; 23(11):2992-2993. PubMed ID: 23071263
    [No Abstract]   [Full Text] [Related]  

  • 14. A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma.
    Pal S; Azad A; Bhatia S; Drabkin H; Costello B; Sarantopoulos J; Kanesvaran R; Lauer R; Starodub A; Hauke R; Sweeney CJ; Hahn NM; Sonpavde G; Richey S; Breen T; Kremmidiotis G; Leske A; Doolin E; Bibby DC; Simpson J; Iglesias J; Hutson T
    Clin Cancer Res; 2015 Aug; 21(15):3420-7. PubMed ID: 25788492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors.
    Kopecky J; Kubecek O; Buchler T; Melichar B; Poprach A; Zemanova M; Katolicka J; Kiss I; Hajek J; Studentova H; Spisarova M
    In Vivo; 2021; 35(5):2981-2990. PubMed ID: 34410998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma.
    Leonetti A; Leonardi F; Bersanelli M; Buti S
    Ther Clin Risk Manag; 2017; 13():799-806. PubMed ID: 28721060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast Cancer.
    Chavez-MacGregor M; Miao J; Pusztai L; Goetz MP; Rastogi P; Ganz PA; Mamounas EP; Paik S; Bandos H; Razaq W; O'Dea A; Kaklamani V; Silber ALM; Flaum LE; Andreopoulou E; Wendt AG; Carney JF; Sharma P; Gralow JR; Lew DL; Barlow WE; Hortobagyi GN
    J Clin Oncol; 2024 Sep; 42(25):3012-3021. PubMed ID: 38833643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus for Children With Recurrent or Progressive Low-Grade Glioma: Results From the Phase II PNOC001 Trial.
    Haas-Kogan DA; Aboian MS; Minturn JE; Leary SES; Abdelbaki MS; Goldman S; Elster JD; Kraya A; Lueder MR; Ramakrishnan D; von Reppert M; Liu KX; Rokita JL; Resnick AC; Solomon DA; Phillips JJ; Prados M; Molinaro AM; Waszak SM; Mueller S
    J Clin Oncol; 2024 Feb; 42(4):441-451. PubMed ID: 37978951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma.
    Albiges L; Chamming's F; Duclos B; Stern M; Motzer RJ; Ravaud A; Camus P
    Ann Oncol; 2012 Aug; 23(8):1943-1953. PubMed ID: 22689175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mTOR Inhibition Prolongs Survival and Has Beneficial Effects on Heart Function After Onset of Lamin A/C Gene Mutation Cardiomyopathy in Mice.
    Wu W; Jin Q; Östlund C; Tanji K; Shin JY; Han J; Leu CS; Kushner J; Worman HJ
    Circ Heart Fail; 2024 Apr; 17(4):e011110. PubMed ID: 38567527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.